Jubilant Life Sciences receives approval to make drug for pain reduction
DSIJ Intelligence / 28 Aug 2017
To produce a drug to treat moderate to severe inflammation and reduce pain, pharmaceutical major Jubilant Life Sciences has received the final approval for the Abbreviated New Drug Application (ANDA) of Indomethacin Capsules USP, 25 mg and 50 mg.
To produce a drug to treat moderate to severe inflammation and reduce pain, pharmaceutical major Jubilant Life Sciences has received the final approval for the Abbreviated New Drug Application (ANDA) of Indomethacin Capsules USP, 25 mg and 50 mg. The approval is for its wholly-owned subsidiary.
Indomethacin Capsules USP is the generic version of Indocin of Iroko, which is a non-steroidal anti-inflammatory drug. It marks for the company the seventh approval that it has received from the USFDA during the current financial year. As on June 30, 2017, Jubilant had a total of 84 ANDAs for oral solids filed in the US, of which 53 have been approved.
The share price of Jubilant Life Sciences increased 0.56% and was trading at Rs 723.25 during the pre-market session on Monday. The stock’s adjusted 52-week high stood at Rs 879.10 (April 12, 2017) and adjusted 52-week low at Rs 496.60 (August 29, 2016).
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.